Pediatric HIV Disclosure Intervention and Benefits Study-(PH-DIBS)
Project Number7R01HD103512-05
Former Number5R01HD103512-04
Contact PI/Project LeaderPAINTSIL, ELIJAH Other PIs
Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
PROJECT SUMMARY
The project aims to assess the effectiveness, health benefits, and cost and obtain information to inform scale-
up and sustainability ofa novel pediatric HIV disclosure intervention (“Sankofa”) among dyads of caregivers
and children 7-18 years of age (who do not know their HIV diagnosis) in Ghana. This area of investigation is
profoundly understudied and of high importance to millions of children and their families in sub-Saharan
Africa. While widely recognized as vital to better health outcomes, especially in the era of better access to
HIV treatment, many children are not informed of their HIV diagnosis. A variety of socio-cultural contextual
barriers and deficient skills drive the persistent reluctance of caregivers and health care providers to inform
children of the diagnosis. We developed a clinic-based disclosure intervention delivered as an integral
component of routine care. The intervention, `Sankofa', is guided by an HIV pediatric disclosure model that
incorporates bioecological systems theory and core elements of the Information-Motivation-Behavioral Skills
(IMB) model of Health Behavior Change. The intervention is the first randomized trial to evaluate the effect of a
structured disclosure intervention on disclosure of HIV status to children. At one year (primary endpoint),
51.4% of children in the Sankofa group had been disclosed to versus 16.2% in the control (p<0.001). While
highly promising, the Sankofa intervention has only been examined in a single site under optimal conditions.
In this study, we aim to build upon the successful Sankofa trial by testing the intervention in a larger scale
study delivered in “real-world” clinic conditions over time in Ghana. We will conduct a pragmatic, stepped
wedge cluster randomized trial in 12 HIV pediatric clinics in Ghana to determine effectiveness, health benefits,
cost and obtain information to inform scale-up and sustainability. We will recruit dyads of 720 children (ages 7-
18) and their caregivers. We propose the following specific aims: (1) To examine the effectiveness of the
Sankofa pediatric disclosure intervention in the presence of “real-world” clinic conditions in Ghana; (2) Assess
health benefits and cost-effectiveness of the Sankofa pediatric disclosure intervention-assisted disclosure as it
pertains to medication adherence and health outcomes of children (virologic, immunologic, psychosocial,
behavioral) and the caregiver (psychosocial); and (3) To explore factors associated with effective
implementation and maintenance of the Sankofa pediatric disclosure intervention in the presence of “real-
world” clinic conditions in Ghana. Our findings will further a scientific understanding of the mechanisms of
action, cost, and individual (child and caregiver)- and organizational-level facilitators and barriers to effective
and sustainable delivery of the intervention in a variety of clinical settings.
Public Health Relevance Statement
PROJECT NARRATIVE
A culturally-relevant, theoretically and empirically sound, patient-centered, standardized disclosure
intervention that can be integrated into routine clinical pediatric HIV care that has the potential to prevent
transmission and improve the welfare of children and their caregivers in low- and middle-income countries. We
aim to build upon the successful Sankofa study by conducting a pragmatic, stepped wedge cluster randomized
trial in high prevalence regions in Ghana to inform the benefits of pediatric HIV disclosure.
Eunice Kennedy Shriver National Institute of Child Health and Human Development
CFDA Code
865
DUNS Number
604483045
UEI
FBYMGMHW4X95
Project Start Date
15-August-2020
Project End Date
30-June-2025
Budget Start Date
22-February-2024
Budget End Date
30-June-2024
Project Funding Information for 2023
Total Funding
$655,498
Direct Costs
$520,507
Indirect Costs
$134,991
Year
Funding IC
FY Total Cost by IC
2023
Eunice Kennedy Shriver National Institute of Child Health and Human Development
$655,498
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 7R01HD103512-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7R01HD103512-05
Patents
No Patents information available for 7R01HD103512-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7R01HD103512-05
Clinical Studies
No Clinical Studies information available for 7R01HD103512-05
News and More
Related News Releases
No news release information available for 7R01HD103512-05
History
No Historical information available for 7R01HD103512-05
Similar Projects
No Similar Projects information available for 7R01HD103512-05